Seminars in Diagnostic Pathology
Volume 28, Issue 3 , Pages 214-233 , August 2011

Primary cutaneous lymphomas: a reprisal

  • Alessandro Pileri Jr, MD

      Affiliations

    • Department of Internal Medicine, Geriatrics, and Nephrology, Division of Dermatology, University of Bologna, Bologna, Italy
    • Corresponding Author InformationAddress reprint requests and correspondence: Alessandro Pileri Jr, MD, Department of Internal Medicine, Geriatrics, and Nephrology, Division of Dermatology, University of Bologna, Via Massarenti 1, 40138 Bologna, Italy
    • ,
  • Annalisa Patrizi, MD

      Affiliations

    • Department of Internal Medicine, Geriatrics, and Nephrology, Division of Dermatology, University of Bologna, Bologna, Italy
    • ,
  • Claudio Agostinelli, MD, PhD

      Affiliations

    • Department of Haematology and Oncological Sciences “L. and A. Seràgnoli,” Bologna University School of Medicine, Bologna, Italy
    • ,
  • Iria Neri, MD

      Affiliations

    • Department of Internal Medicine, Geriatrics, and Nephrology, Division of Dermatology, University of Bologna, Bologna, Italy
    • ,
  • Elena Sabattini, MD

      Affiliations

    • Department of Haematology and Oncological Sciences “L. and A. Seràgnoli,” Bologna University School of Medicine, Bologna, Italy
    • ,
  • Francesco Bacci, MD

      Affiliations

    • Department of Haematology and Oncological Sciences “L. and A. Seràgnoli,” Bologna University School of Medicine, Bologna, Italy
    • ,
  • Pier Paolo Piccaluga, MD, PhD

      Affiliations

    • Department of Haematology and Oncological Sciences “L. and A. Seràgnoli,” Bologna University School of Medicine, Bologna, Italy
    • ,
  • Nicola Pimpinelli, MD

      Affiliations

    • Department of Critical Care, Medicine and Surgery, Section of Dermatology, University of Florence, Florence, Italy
    • ,
  • Stefano A. Pileri, MD

      Affiliations

    • Department of Haematology and Oncological Sciences “L. and A. Seràgnoli,” Bologna University School of Medicine, Bologna, Italy

References 

  1. Bradford PT, Devesa SS, Anderson WF, et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113:5064–5073
  2. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007;25:1581–1587
  3. Kodama K, Massone C, Chott A, et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood. 2005;106:2491–2497
  4. Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol. 2006;24:1376–1382
  5. Berti E, Alessi E, Caputo R, et al. Reticulohistiocytoma of the dorsum. J Am Acad Dermatol. 1988;19:259–272
  6. Cerroni L, Arzberger E, Pütz B, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood. 2000;95:3922–3928
  7. Goodlad JR, Krajewski AS, Batstone PJ, et al. Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity. Am J Surg Pathol. 2002;26:733–741
  8. de Leval L, Harris NL, Longtine J, et al. Cutaneous B-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol. 2001;25:732–741
  9. Goodlad JR, Krajewski AS, Batstone PJ, et al. Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes. Am J Surg Pathol. 2003;27:1538–1545
  10. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol. 2003;149:1183–1191
  11. Kim BK, Surti U, Pandya A, et al. Clinicopathologic, immunophenotypic, and molecular cytogenetic fluorescence in situ hybridization analysis of primary and secondary cutaneous follicular lymphomas. Am J Surg Pathol. 2005;29:69–82
  12. Mirza I, Macpherson N, Paproski S, et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol. 2002;20:647–655
  13. Fanoni D, Tavecchio S, Recalcati S, et al: New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas. Immunol Lett, Jan 30 134:157-160
  14. Cerroni L, Volkenandt M, Rieger E, et al. Bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J Invest Dermatol. 1994;102:231–235
  15. Child FJ, Russell-Jones R, Woolford AJ, et al. Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma. Br J Dermatol. 2001;144:735–744
  16. Geelen FA, Vermeer MH, Meijer CJ, et al. Bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol. 1998;16:2080–2085
  17. Vergier B, Belaud-Rotureau MA, Benassy MN, et al. Neoplastic cells do not carry bcl2-JH rearrangements detected in a subset of primary cutaneous follicle center B-cell lymphomas. Am J Surg Pathol. 2004;28:748–755
  18. Aarts WM, Willemze R, Bende RJ, et al. VH gene analysis of primary cutaneous B-cell lymphomas: evidence for ongoing somatic hypermutation and isotype switching. Blood. 1998;92:3857–3864
  19. Dijkman R, Tensen CP, Jordanova ES, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol. 2006;24:296–305
  20. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105:3671–3678
  21. Vermeer MH, Geelen FA, van Haselen CW, et al. Primary cutaneous large B-cell lymphomas of the legs (A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis). Arch Dermatol. 1996;11:1304–1308
  22. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785
  23. Patrizi A, Raone B, Sabattini E, et al. Primary cutaneous large B-cell lymphoma, leg type, localized on the dorsum. Case Rep Dermatol. 2009;1:87–92
  24. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol. 2001;19:3602–3610
  25. Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004;103:3662–3668
  26. Kriangkum J, Taylor BJ, Treon SP, et al. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood. 2004;104:2134–2142
  27. Hallermann C, Kaune KM, Gesk S, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol. 2004;123:213–219
  28. Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. Am J Surg Pathol. 2010;34:1830–1841
  29. Swerdlow S, Campo E, Harris N, et al. WHO CLassification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008;
  30. Jaffe E, Harris NL, Stein H, et al. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2001;
  31. Falini B, Tiacci E, Pucciarini A, et al. Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). Blood. 2003;102:3684–3692
  32. Pileri SA, Zinzani PL, Went P, et al. Indolent lymphoma: the pathologist's viewpoint. Ann Oncol. 2004;15:12–18
  33. Vonderheid EC, Pena J, Nowell P. Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging. Leuk Lymphoma. 2006;47:1841–1856
  34. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713–1722
  35. Cerroni L. Lymphoproliferative lesions of the skin. J Clin Pathol. 2006;59:813–826
  36. Massone C, Kodama K, Kerl H, et al. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol. 2005;29:550–560
  37. Cerroni L, Rieger E, Hödl S, et al. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am J Surg Pathol. 1992;16:543–552
  38. Diamandidou E, Colome-Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood. 1998;92:1150–1159
  39. Vergier B, de Muret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases (French Study Group of Cutaneious Lymphomas). Blood. 2000;95:2212–2218
  40. Massone C, Crisman G, Kerl H, et al. The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality. Br J Dermatol. 2008;159:881–886
  41. Klemke CD, Fritzsching B, Franz B, et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia. 2006;20:1123–1129
  42. Berger CL, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood. 2005;105:1640–1647
  43. Liso A, Capello D, Marafioti T, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood. 2006;108:1013–1020
  44. Thangavelu M, Finn WG, Yelavarthi KK, et al. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome. Blood. 1997;89:3371–3377
  45. Tracey L, Villuendas R, Dotor AM, et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood. 2003;102:1042–1050
  46. Pileri A, Facchetti F, Rutten A, et al: Syringotropic mycosis fungoides: a rare variant of the disease with peculiar clinicopathologic features. Am J Surg Pathol, Jan 35:100-109
  47. van Haselen CW, Toonstra J, van der Putte SJ, et al. Granulomatous slack skin (Report of three patients with an updated review of the literature). Dermatol Basel Switzerland. 1998;196:382–391
  48. Trotter MJ, Whittaker SJ, Orchard GE, et al. Cutaneous histopathology of Sézary syndrome: a study of 41 cases with a proven circulating T-cell clone. J Cutan Pathol. 1997;24:286–291
  49. Scheffer E, Meijer CJ, van Vloten WA, et al. A histologic study of lymph nodes from patients with the Sézary syndrome. Cancer. 1986;57:2375–2380
  50. Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells. Br J Dermatol. 2001;144:125–135
  51. Narducci MG, Scala E, Bresin A, et al. Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood. 2006;107:1108–1115
  52. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome. Clin Exp Dermatol. 2005;30:702–706
  53. Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767–771
  54. Fierro MT, Comessatti A, Quaglino P, et al. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sezary syndrome. Dermatol Basel Switzerland. 2006;213:284–292
  55. Batista DA, Vonderheid EC, Hawkins A, et al. Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: search for recurrent chromosome abnormalities. Genes Chromosomes Cancer. 2006;45:383–391
  56. Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides. Br J Dermatol. 2002;147:464–475
  57. Mao X, Lillington DM, Czepulkowski B, et al. Molecular cytogenetic characterization of Sézary syndrome. Genes Chromosomes Cancer. 2003;36:250–260
  58. Drexler HG, Gignac SM, von Wasielewski R, et al. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia. 2000;14:1533–1559
  59. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653–3661
  60. Paulli M, Berti E, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin—clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol. 1995;13:1343–1354
  61. de Bruin PC, Beljaards RC, van Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology. 1993;23:127–135
  62. DeCoteau JF, Butmarc JR, Kinney MC, et al. (2; 5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood. 1996;87:3437–3441
  63. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol. 2000;53:445–450
  64. Natkunam Y, Warnke RA, Haghighi B, et al. Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases. J Cutan Pathol. 2000;27:392–399
  65. Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111:838–845
  66. Gonzalez CL, Medeiros LJ, Braziel RM, et al. T-cell lymphoma involving subcutaneous tissue (A clinicopathologic entity commonly associated with hemophagocytic syndrome). Am J Surg Pathol. 1991;15:17–27
  67. Massone C, Lozzi GP, Egberts F, et al. The protean spectrum of non-Hodgkin lymphomas with prominent involvement of subcutaneous fat. J Cutan Pathol. 2006;33:418–425
  68. Kumar S, Krenacs L, Medeiros J, et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol. 1998;29:397–403
  69. Arnulf B, Copie-Bergman C, Delfau-Larue MH, et al. Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood. 1998;91:1723–1731
  70. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol. 1998;22:881–893
  71. Toro JR, Beaty M, Sorbara L, et al. Gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol. 2000;136:1024–1032
  72. Tsukamoto Y, Katsunobu Y, Omura Y, et al. Subcutaneous panniculitis-like T-cell lymphoma: successful initial treatment with prednisolone and cyclosporin A. Intern Med Tokyo Jpn. 2006;45:21–24
  73. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101:3407–3412
  74. Berti E, Cerri A, Cavicchini S, et al. Primary cutaneous gamma/delta T-cell lymphoma presenting as disseminated pagetoid reticulosis. J Invest Dermatol. 1991;96:718–723
  75. Jones D, Vega F, Sarris AH, et al. CD4-CD8-“Double-negative” cutaneous T-cell lymphomas share common histologic features and an aggressive clinical course. Am J Surg Pathol. 2002;26:225–231
  76. de Wolf-Peeters C, Achten R. Gammadelta T-cell lymphomas: a homogeneous entity?. Histopathology. 2000;36:294–305
  77. Munn SE, McGregor JM, Jones A, et al. Clinical and pathological heterogeneity in cutaneous gamma-delta T-cell lymphoma: a report of three cases and a review of the literature. Br J Dermatol. 1996;135:976–981
  78. Ralfkiaer E, Wollf-Sneedorff A, Thomsen K, et al. T-cell receptor gamma delta-positive peripheral T-cell lymphomas presenting in the skin: a clinical, histological and immunophenotypic study. Exp Dermatol. 1992;1:31–36
  79. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol. 2003;40:175–184
  80. Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. 2004;28:719–735
  81. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas (A distinct clinicopathological entity with an aggressive clinical behavior). Am J Pathol. 1999;155:483–492
  82. Marzano AV, Ghislanzoni M, Gianelli U, et al. Fatal CD8+ epidermotropic cytotoxic primary cutaneous T-cell lymphoma with multiorgan involvement. Dermatol Basel Switzerland. 2005;211:281–285
  83. Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas (Report of EORTC Cutaneous Lymphoma Task Force Workshop). Cancer. 2003;97:610–627
  84. Agnarsson BA, Vonderheid EC, Kadin ME. Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: identification of rapidly progressive and chronic subtypes. J Am Acad Dermatol. 1990;22:569–577
  85. Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003;102:2213–2219
  86. Garcia-Herrera A, Colomo L, Camós M, et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol. 2008;26:3364–3371
  87. Sterry W, Siebel A, Mielke V. HTLV-1-negative pleomorphic T-cell lymphoma of the skin: the clinicopathological correlations and natural history of 15 patients. Br J Dermatol. 1992;126:456–462
  88. Friedmann D, Wechsler J, Delfau MH, et al. The French Study Group on Cutaneous Lymphomas Primary cutaneous pleomorphic small T-cell lymphoma (A review of 11 cases). Arch Dermatol. 1995;131:1009–1015
  89. Beljaards RC, Meijer CJ, Van der Putte SC, et al. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma. J Pathol. 1994;172:53–60
  90. Rodríguez-Pinilla SM, Roncador G, Rodríguez-Peralto JL, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol. 2009;33:81–90
  91. Fink-Puches R, Zenahlik P, Bäck B, et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 2002;99:800–805
  92. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol. 2002;10:7–14
  93. Cho KH, Kim CW, Heo DS, et al. Epstein-Barr virus-associated peripheral T-cell lymphoma in adults with hydroa vacciniforme-like lesions. Clin Exp Dermatol. 2001;26:242–247
  94. Doeden K, Molina-Kirsch H, Perez E, et al. Hydroa-like lymphoma with CD56 expression. J Cutan Pathol. 2008;35:488–494
  95. Chen HH, Hsiao CH, Chiu HC. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma. Br J Dermatol. 2002;147:587–591
  96. Nitta Y, Iwatsuki K, Kimura H, et al. Fatal natural killer cell lymphoma arising in a patient with a crop of Epstein-Barr virus-associated disorders. Eur J Dermatol. 2005;15:503–506

PII: S0740-2570(11)00042-6

doi: 10.1053/j.semdp.2011.04.002

Seminars in Diagnostic Pathology
Volume 28, Issue 3 , Pages 214-233 , August 2011

Article Tools

* Image Usage & Resolution